Development of asystole requiring cardiac resuscitation after the administration of regadenoson in a patient with pulmonary fibrosis receiving n-acetylcysteine

Journal of Nuclear Cardiology

Volumn 18, Issue 3, 2011, Pages 521-525

  Grady, Erin C ^a   Barron, John T ^a   Wagner, Robert H ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; AMINOPHYLLINE; AZATHIOPRINE; REGADENOSON; ROSUVASTATIN;

ADULT; ARTICLE; ASYSTOLE; ATRIOVENTRICULAR BLOCK; CASE REPORT; DECOMPRESSION; DIAPHORESIS; DIZZINESS; DYSPNEA; ELECTROCARDIOGRAM; HUMAN; LUNG FIBROSIS; LUNG FUNCTION TEST; MALE; MYOCARDIAL PERFUSION IMAGING; NAUSEA; PATIENT ASSESSMENT; PRIORITY JOURNAL; RESUSCITATION; SIDE EFFECT; SINUS ARREST; UNCONSCIOUSNESS;

ACETYLCYSTEINE; ADENOSINE A2 RECEPTOR ANTAGONISTS; DRUG INTERACTIONS; EXPECTORANTS; HEART ARREST; HUMANS; MALE; MIDDLE AGED; PULMONARY FIBROSIS; PURINES; PYRAZOLES;

EID: 79960410488     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-011-9373-0     Document Type: Article

References (16)

1. 2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. JACC 2005;46:2069-75. (Pubitemid 41713594)
2. TM) product insert, revised January 2009.
3. Garnock-Jones K, Curran M. Regadenoson. Am J Cardiovasc Drugs 2010;10:65-71.
4. Thomas G, Thompson R, Miyamoto M, Ip T, Rice D, Milikien D, et al. The RegEx trial: A randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2009;16:63-72.
5. Al Jaroudi W, Iskandrain A. Regadenoson: A new myocardial stress agent. JACC 2009;54:1123-30.
6. Van Gaal W, Couthino B, Chan M, Allman K. The safety and tolerability of adenosine in patients with obstructive airways disease. Int J Cardiol 2008;128:436-8.
7. Johnston D, Scanlon P, Hodge D, Glynn R, Hung J, Gibbons R. Pulmonary function monitoring during adenosine myocardial perfusion scintigraphy in patients with chronic obstructive pulmonary disease. Mayo Clin Proc 1999;74:339-46. (Pubitemid 29162533)
8. Reyes E, Loong C, Wechalekar K, Latus K, Anagnostopoulos C, Underwood S. Side effect profile and tolerability of adenosine myocardial perfusion scintigraphy in patients with mild asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 2007;14: 827-34. Epub 2007 Oct 18. (Pubitemid 350082577)
9. Jacobson K, Gao Z. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5:247-64. (Pubitemid 43336037)
10. Manjunath S, Sakhare P. Adenosine and adenosine receptors: Newer therapeutic perspective. Indian J Physiol Pharmacol 2009;41:97-105.
11. Scheibner K, Boodoo S, Collins S, Black K, Chan-Li Y, Zarek P, et al. The adenosine A2a receptor inhibits matrix-induced inflam-mationinanovel fashion.AmJRespir Cell Mol Biol 2009;40:251-9.
12. Vass G, Horvath I. Adenosine and adenosine receptors in the pathomechanism and treatment of respiratory diseases. Curr Med Chem 2008;15:917-22. (Pubitemid 351736412)
13. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen H, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42. (Pubitemid 41697286)
14. Millea P. N-acetylcysteine: Multiple clinical applications. Am Fam Physician 2009;80:265-9.
15. Kati W, Acheson S, Wolfenden R. A transition state in pieces: Major contributions of entropic effects to ligand binding by adenosine deaminase. Biochemistry 1992;31:7356-66.
16. Jones W, Kurz L, Wolfenden R. Transition-state stabilization by adenosine deaminase: 1, 6-addition of water to purine ribonucleo-side, the enzyme's affinity for 6-hydroxy-1, 6-dihydropurine ribonucleoside, and the effective concentration of substrate water at the active site. Biochemistry 1989;28:1242-7. (Pubitemid 19058698)